



Supplemental Fig. 2 Investigation of carryover effect comparing $2 \mu\text{g mL}^{-1}$ nivolumab-spiked serum digests with mobile phase after injection of $200 \mu\text{g mL}^{-1}$ nivolumab-spiked serum digests.

(A) The peak of surrogate peptide in $2 \mu\text{g mL}^{-1}$ nivolumab-spiked serum digests.

(B) The peak of surrogate peptide in mobile phase after injection of $200 \mu\text{g mL}^{-1}$ nivolumab-spiked serum digests.